Clinical Data Launches PGxPredict(TM):RITUXIMAB on Schedule.

Pharmacogenetic Test to Aid Physicians in Managing Therapy for Patients with Follicular non-Hodgkin's Lymphoma

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA), announced today that its PGxHealth[TM] division, provider of Therapeutic Diagnostics[TM], has launched a new test, PGxPredict[TM]:RITUXIMAB, further strengthening its leadership position within the rapidly evolving fields of pharmacogenetics and molecular diagnostics. This is the second pharmacogenetic test of its kind launched by PGxHealth this month. The assay is based on a worldwide exclusive license to an intellectual property portfolio from Innate Pharma S.A. of Marseille, France.

PGxPredict:RITUXIMAB is a pharmacogenetic test that helps physicians predict the likelihood of a given patient responding to rituximab monotherapy in the treatment of follicular non-Hodgkin's lymphoma (NHL). This test allows oncologists to identify whether a patient is among the 20% of people that will demonstrate a stronger likelihood of responding to rituximab.

"PGxPredict:RITUXIMAB is the third PGxPredict test that Clinical Data has launched in the last four months. We are very pleased and excited that we can bring pharmacogenetic tests like these to market rapidly and provide physicians with more information when making important clinical decisions with their patients," said Drew Fromkin, CEO of Clinical Data. "For the first time in this life-threatening disease, physicians can consider the genetic makeup of each patient in evaluating the likelihood of response to rituximab. Having this information will assist physicians when considering treatment options."

This new genetic test will provide unique and valuable information for patients with follicular NHL and their doctors. By analyzing a person's DNA from a blood sample, the test identifies a single nucleotide polymorphism, referred to as V158F, in the FCGR3A gene. This gene encodes the Fc gamma IIIa receptor on lymphocytes to which rituximab binds. Based on two independent studies in 49 and 87 patients, respectively, patients with follicular, CD20-positive, B-cell NHL who carried the 158V/V version of the variant in the FCGR3A gene were more likely to respond to rituximab monotherapy than patients with other variants. This association held true when response was measured at both 2-month and 12-month end points.1,2 In addition, functional characterization of this variant has shown altered binding affinity of IgG1 antibodies, including rituximab, to the Fc gamma IIIa receptor.3

Based on this published data, approximately 20% of patients will carry the 158V/V variant and will be identified by the PGxPredict:RITUXIMAB test as more likely to respond (estimated response rate of 90%). Approximately half of those who do not carry the 158V/V variant may still respond to rituximab monotherapy. The assay will detect the variant with over 99% accuracy, based on the method validation performed by the testing laboratory, Cogenics, Inc., a subsidiary of Clinical Data.

While rituximab has proven to be valuable in the treatment of patients with follicular, CD20-positive NHL, its high cost of approximately $12,000 for four weekly treatments, and risk of toxicity may make the choice to prescribe or maintain therapy with rituximab a difficult one for physicians and patients, especially with other treatment options available. The PGxPredict:RITUXIMAB test will provide unique and valuable information to physicians and patients as they evaluate their treatment options.

For more information on the PGxPredict:RITUXIMAB test, please visit http://www.pgxhealth.com or call 1-877-4-RITUXIMAB (877-474-8894) or email [e-mail].

About Follicular NHL and Rituximab

Globally, NHL is the sixth leading cause of new cancer cases with the incidence rising and estimated to be 5.6 per 100,000 persons, though the incidence varies geographically.4 NHL has the highest incidence in the United States, Australia and New Zealand, and Europe. The incidence in the United States is 17.1 per 100,000 with approximately 22% of all cases of NHL belonging to the follicular subtype.4,5

Rituximab (Rituxan([R]), Genentech and Biogen Idec) is an IgG1 immunotherapeutic agent indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell, non-Hodgkin's lymphoma, for the first line treatment of follicular, CD20-positive, B-cell non-Hodgkin's lymphoma in combination with CVP chemotherapy, for the treatment of low-grade, CD20-positive, B-cell non-Hodgkin's lymphoma in patients with stable disease or who achieve a partial or complete response following first-line treatment with CVP chemotherapy and for the first-line treatment of diffuse large B-cell, CD20-positive, non-Hodgkin's lymphoma in combination with CHOP or other anthracycline-based chemotherapy regimens.

Rituximab costs approximately $12,000 for a 4-week course of treatment for NHL, although insurance companies typically pay a significant portion of the cost. Per the rituximab package insert, the overall response rate to monotherapy is 57% at week 8 with weekly dosing in relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL. In patients receiving single agent rituximab for treatment of relapsed or refractory, low grade or follicular NHL, Grade 3 and 4 adverse events overall were reported in 57% of patients treated with 4 weekly doses and in 70% of patients treated with 8 weekly doses of rituximab. See package insert for full prescribing information.

Rituximab is sold as Rituxan in the United States. All trademarks are property of their respective owners.

About PGxHealth

PGxHealth[TM] has extensive experience and capabilities in the development, clinical validation and delivery of genomic-based tests, in particular of efficacy and safety biomarkers for appropriate drug utilization. Through its own know-how and resources, work conducted with some of the world's most prestigious genomics thought leaders and institutions, and use of innovative technologies, PGxHealth is focused on reducing treatment costs and improving clinical outcomes in those disease states and therapeutic classes beset with expensive, inefficient, or suboptimal treatment options. It has branded its genetic tests based on these proprietary genetic markers Therapeutic Diagnostics[TM].

In addition to PGxPredict:RITUXIMAB, PGxHealth provides the following genetic tests to practitioners: FAMILION([R]), a genetic test designed to identify mutations in people with inherited cardiac channelopathies such as Long QT Syndrome (LQTS) and Brugada Syndrome; PGxPredict[TM]:WARFARIN, a pharmacogenetic test that measures variation in 2 genes related to response to warfarin; a pharmacogenetic assay that tests for mutations in the thiopurine S-methyl transferase (TPMT) gene, exclusively licensed from St. Jude Children's Research Hospital and offered through Prometheus Laboratories Inc. and Specialty Laboratories (a wholly owned subsidiary of Ameripath, Inc.), that provides an assessment of a patient's ability to metabolize the thiopurine class of drugs, prescribed in a wide range of therapeutic areas including oncology, rheumatology, organ transplantation and vasculitis; and PGxPredict[TM]:CLOZAPINE, a pharmacogenetic test designed to aid physicians prescribing or considering prescribing clozapine that will provide information on whether a patient is at Higher or Lower Risk of developing clozapine-induced agranulocytosis (CIA) compared to the untested population.

About Clinical Data, Inc.

Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, from targeted science to better healthcare. Its PGxHealth division focuses on genetic test and biomarker development to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics division provides molecular and pharmacogenomics services to both research and regulated environments. Its Vital Diagnostics division offers in vitro diagnostics solutions for the clinical laboratory. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists, and health plans worldwide.

About Innate Pharma S.A.

Innate Pharma S.A. (Euronext Paris: FR0010331421 - IPH) is a biopharmaceutical company which develops first-in-class drugs to target innate immunity. The pioneering work of Innate Pharma's scientific founders and research groups has led to the development of three product platforms (gamma delta T cells, NK cells and TLR), each directly or indirectly validated in clinical oncology settings. In view of their mechanisms of action, Innate Pharma's drug candidates also have development potential in fields outside oncology, particularly in the treatment of infectious disease and chronic inflammation. The company's most advanced molecule is in Phase II clinical trials. With its strong scientific position in innate immunity pharmacology, its robust intellectual property portfolio and its R&D expertise, Innate Pharma intends to become a leading player in the rapidly growing market of immunotherapeutics.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to statements regarding: our ability to successfully integrate the operations, business, technology and intellectual property obtained in our acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether our PGxPredict tests will gain wide acceptance in the market; the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety; our ability to achieve the expected synergies and operating efficiencies from all of our acquisitions; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; general economic downturns; and other risks contained in our various SEC reports and filings, including but not limited to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2006, and our subsequent Current Reports on Form 8-K filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Internet Website: www.clda.com

References

1 Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P and Watier H. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc[eth][thorn]RIIIa gene. Blood, 99: 754-758.

2 Weng W-K and Levy R. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of Clinical Oncology, 21(21): 3940-3947.

3 Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, and Thibault G. 2004. Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on concentration-effect relationship. Cancer Research, 64:4664-4669.

4 Ferlay J, Bray F, Pisani P and Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5. version 2.0, IARCPress, Lyon, 2004

5 Evans LS, and Hancock BW. 2003. Non-Hodgkin's Lymphoma. Lancet, 362:139-146.